Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis
Actas Dermosifiliogr. 2017 May;108(4):305-314.
doi: 10.1016/j.ad.2016.09.021.
Epub 2016 Nov 22.
[Article in
English,
Spanish]
Affiliations
- 1 Department of Dermatology, Centro Hospitalar do Porto, Portugal.
- 2 Department of Dermatology, Centro Hospitalar do Porto, Portugal; Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal. Electronic address: torres.tiago@outlook.com.
Abstract
Psoriasis is a common, chronic, inflammatory skin disorder with a physical and emotional burden. Emerging evidence suggests that IL17-A is a key cytokine in the immunopathogenesis of psoriasis. Ixekizumab is a humanized IgG4 monoclonal antibody that acts by neutralizing IL-17A. Data from Phase I-III studies reveal that ixekizumab is highly effective in treating patients with moderate-to-severe plaque psoriasis. A large proportion of patients receiving ixekizumab achieved or maintained complete or near complete resolution of psoriatic lesions with an acceptable safety profile through week 60. These remarkable results introduce a paradigm shift in the medically management of psoriasis, where complete or almost completely clear skin becomes the new therapeutic goal.
Keywords:
Agentes anti IL-17; Anti-IL-17 agents; Interleucina-17; Interleukin-17; Ixekizumab; Psoriasis.
Copyright © 2016 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / immunology
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antibodies, Neutralizing / adverse effects
-
Antibodies, Neutralizing / immunology
-
Antibodies, Neutralizing / therapeutic use
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / immunology
-
Antirheumatic Agents / therapeutic use*
-
Candidiasis, Chronic Mucocutaneous / etiology
-
Clinical Trials as Topic
-
Disease Susceptibility
-
Double-Blind Method
-
Etanercept / adverse effects
-
Etanercept / therapeutic use
-
Headache / etiology
-
Humans
-
Interleukin-17 / antagonists & inhibitors*
-
Interleukin-17 / immunology
-
Interleukin-17 / physiology
-
Psoriasis / drug therapy*
-
Psoriasis / immunology
-
Randomized Controlled Trials as Topic
-
Respiratory Tract Infections / etiology
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Neutralizing
-
Antirheumatic Agents
-
IL17A protein, human
-
Interleukin-17
-
ixekizumab
-
secukinumab
-
Etanercept